PHILADELPHIA, PA / ACCESSWIRE / September 25, 2024 / Prevail Partners LLC ("Prevail Partners") and Prevail InfoWorks Inc. ("Prevail InfoWorks") announce that they have entered into a strategic ...

Dr. Meegan Gruber looks at myths vs. facts on safer, less invasive procedures.TAMPA, FL / ACCESSWIRE / September 25, 2024 / Awake surgery is becoming increasingly popular as patients seek safer, less ...

WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that ...

Orion Corporation and Aitia, an AI-enabled biotechnology company and the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, announced today ...

Amsterdam, Netherlands) A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in ...

Treatment of patients in intensive care units (ICUs) would significantly expand Ondine’s market opportunity.Infection prevention is a top priority in ICUs as they face higher infection rates, more ...

Miles Congreve, Chief Scientific Officer of Isomorphic Labs to join Arctoris Scientific Advisory BoardOxford, UK and Boston, USA. 25 September 2024.  Arctoris (‘Arctoris’ or ‘the Company’), a leading ...

Univo IRB, a leader in ethical review and oversight for clinical research, is proud to announce the launch of its Canadian research ethics board (REB) review services. This new offering is designed to ...

Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to ...

AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral neuropathic pain, ATX01, announced today the completion of the Last Patient Last ...

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary ...

Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing authorization application (MAA) for AGAMREE® ...